We assessed the relationship between phasing out stavudine in first-line antiretroviral therapy (ART) in accordance with WHO 2010 policy and single-drug substitutions (SDS) (substituting the nucleoside reverse transcriptase inhibitor in first-line ART) in sub-Saharan Africa.
Prospective cohort analysis (International epidemiological Databases to Evaluate AIDS-Multiregional) including ART-naive, HIV-infected patients aged at least 16 years, initiating ART between January 2005 and December 2012. Before April 2010 (July 2007 in Zambia) national guidelines called for patients to initiate stavudine-based or zidovudine-based regimen, whereas thereafter tenofovir or zidovudine replaced stavudine in first-line ART.
We evaluated the frequency of stavudine use and SDS by calendar year 2004–2014. Competing risk regression was used to assess the association between nucleoside reverse transcriptase inhibitor use and SDS in the first 24 months on ART.
In all, 33 441 (8.9%; 95% confience interval 8.7–8.9%) SDS occurred among 377 656 patients in the first 24 months on ART, close to 40% of which were amongst patients on stavudine. The decrease in SDS corresponded with the phasing out of stavudine. Competing risks regression models showed that patients on tenofovir were 20–95% less likely to require a SDS than patients on stavudine, whereas patients on zidovudine had a 75–85% decrease in the hazards of SDS when compared to stavudine.
The decline in SDS in the first 24 months on treatment appears to be associated with phasing out stavudine for zidovudine or tenofovir in first-line ART in our study. Further efforts to decrease the cost of tenofovir and zidovudine for use in this setting is warranted to substitute all patients still receiving stavudine.
Supplemental Digital Content is available in the text
aDepartment of Global Health, Boston University, Boston, Massachusetts, USA
bHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
cDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
dCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
eDepartment of Infectious Diseases, Bern University Hospital, University of Bern
fInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
gThe Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town
hDivision of Infectious Diseases, Department of Medicine, University of Stellenbosch & Tygerberg Academic Hospital, Cape Town
iAfrica Center for Health and Population Studies, University of Kwazulu-Natal
jKheth’Impilo AIDS Free Living, Cape Town
kDepartment of Health, Provincial Government of the Western Cape, Cape Town, South Africa
lCenter for Infectious Disease Research in Zambia, Lusaka, Zambia
mIndiana University School of Medicine, Indianapolis
nRichard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA
oINSERM U1027, Université Paul Sabatier Toulouse 3, Toulouse
pUniversité Bordeaux, ISPED, Centre INSERM U1219 Epidémiologie-Biostatistique, Bordeaux, France.
Correspondence to Alana T. Brennan, Department of Global Health Boston University Crosstown Center, 3rd Floor, 801 Massachusetts Ave, Boston, MA 02118, USA. Tel: +1 617 414 1179; e-mail: email@example.com
Received 18 May, 2016
Revised 22 September, 2016
Accepted 5 October, 2016
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).